NDAC
This article was originally published in The Tan Sheet
Executive Summary
Meeting slated for Oct. 18-19 has been canceled. No agenda has been set for the next scheduled meeting dates of Dec. 2-3. Most recently, NDAC met jointly with the Arthritis Advisory Committee July 20 to consider the Rx-to-OTC switch of Merck's Flexeril 5 mg (1"The Tan Sheet" July 26, pp. 3-9)